Cover

Device Guide

This Device Guide offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.

Three-Year ABSORB III Trial Data Presented and Published for Abbott Vascular's BVS

 

October 31, 2017—The ABSORB III study assessed clinical outcomes through 3 years after implantation of the Absorb everolimus-eluting poly-L-lactic acid–based bioresorbable vascular scaffold (BVS; Abbott Vascular). The findings were published online by Dean J. Kereiakes, MD, et al in Journal of the American College of Cardiology and simultaneously presented as a late-breaking trial at TCT 2017, the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium being held October 30 to November 2 in Denver, Colorado.

Clinical outcomes from the trial were analyzed by randomized treatment assignment cumulative through 3 years and between 1 and 3 years. Previously, the ABSORB III data demonstrated noninferior rates of target lesion failure (TLF; defined as cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EESs).

As summarized in Journal of the American College of Cardiology, the primary composite endpoint of TLF through 3 years occurred in 13.4% of BVS patients and 10.4% of EES patients (P = .06). Between 1 and 3 years, TLF occurred in 7% of BVS versus 6% of EES patients (P = .39).

Both TVMI and device thrombosis through 3 years were increased with BVS (8.6% vs 5.9%; P = .03 and 2.3% vs 0.7%; P = .01, respectively). In BVS-assigned patients, treatment of very small vessels (quantitatively determined reference vessel diameter < 2.25 mm) was an independent predictor of 3-year TLF and scaffold thrombosis.

The ABSORB III investigators concluded that the 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. They advised that longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.